A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Phase 1/2
265
about 4.8 years
18+
18 sites in CA, DC, FL +11
About this study
Researchers are testing a treatment called EP0031 to see if it's safe and effective for people with advanced RET-altered cancers. The trial will help determine the best dose of this medication.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take EP0031
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Module A: Incidence of Dose-limiting Toxicity (DLTs ) during the first 28 days of EP0031 treatment, Modules B and C: Overall Response Rate (ORR) as measured using RECIST v1.1
Secondary: Area under the plasma concentration versus time curve (AUC), Maximum Plasma Concentration (Cmax), Time taken for drug concentration to fall from half its original value (Half-life)
Oncology